News > Adding anti-inflammatory medicine to Remdesivir shortens time of recovery of COVID-19 patients
Adding anti-inflammatory medicine to Remdesivir shortens time of recovery of COVID-19 patients
Firstpost | 15/09/2020 04:22 PM | Click to read full article
The Eli Lilly and Co drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day.
The study tested Baricitinib, a pill used to treat rheumatoid arthritis. Those who also were given Baricitinib recovered one day sooner than those given Remdesivir alone. Lilly planned to discuss with regulators the possible emergency use of Baricitinib for hospitalized COVID-19 patients.